International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Hervé Dombret(University of London Institute in Paris), Hartmut Döhner(University Hospital Ulm), Anna Candoni(University of Udine), Aleksandra Butrym(Wroclaw Medical University), Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Agnieszka Wierzbowska(Medical University of Lodz), José Falantes(Hospital Universitario Virgen del Rocío), Mark D. Minden(University Health Network), Heidi McIntyre, Dominik Selleslag(National Institutes of Health), Rajat Kumar(University Health Network), James D. Cavenagh(National Health Service), Jun Ho Jang(Samsung Medical Center), Irwindeep Sandhu(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), S. Songer, Lela M. Lucy, Haifa Kathrin Al‐Ali(University Hospital in Halle), Richard M. Stone(Dana-Farber Cancer Institute), Giovanni Martinelli(University of Bologna), John F. Seymour(The Royal Melbourne Hospital), Richard Noppeney(Essen University Hospital), C. L. Beach, Andre C. Schuh(University of Toronto)
Cited by 1,157
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k